Constitutive overproduction of the pump MexXY-OprM is recognized as a major cause of resistance to aminoglycosides, fluoroquinolones, and zwitterionic cephalosporins in Pseudomonas aeruginosa. In this study, 57 clonally unrelated strains recovered from non-cystic fibrosis patients were analyzed to characterize the mutations resulting in upregulation of the mexXY operon. 
P
seudomonas aeruginosa is a frequent cause of nosocomial infections and is associated with progressive lung deterioration in cystic fibrosis (CF) patients. In addition to its elevated intrinsic resistance to many anti-Gram-negative antibiotics, this pathogen is notoriously known for its ability to develop clinically relevant levels of resistance to the most potent antipseudomonal drugs available, including aminoglycosides (e.g., gentamicin, tobramycin, amikacin) (1) . Besides the acquisition of plasmid-and/or integron-borne genes encoding various aminoglycoside-modifying enzymes, the major mechanism by which P. aeruginosa may readily decrease its susceptibility to these agents consists of production of an RND (resistance nodulation cell division family) efflux pump, MexXY-OprM (1). This multispecific active efflux system accommodates a large range of antimicrobials, including zwitterionic cephalosporins (cefepime, cefpirome), macrolides (e.g., erythromycin), fluoroquinolones (e.g., ciprofloxacin), and tetracyclines (e.g., tetracycline, tigecycline), in addition to aminoglycosides (2) (3) (4) (5) (6) (7) (8) (9) . Ribosome protection experiments have demonstrated that MexXY-OprM contributes to the natural resistance of P. aeruginosa to only those exported substrates able to induce mexXY operon expression, as a result of protein synthesis impairment (10) . Of note, the outer membrane protein OprM, which interacts with the periplasmic adaptor MexX and the RND transporter MexY to form a functional tripartite efflux machinery (2) , is encoded by the constitutively expressed operon mexAB-oprM (11, 12) . This drug-dependent activation of mexXY was found to depend upon the expression of a gene of unknown function, PA5471, itself transcriptionally coupled with a nonessential gene (PA5470) encoding a putative accessory peptide-releasing factor (13) . When P. aeruginosa is exposed to subinhibitory concentrations of ribosome-targeting drugs, such as aminoglycosides, tetracyclines, macrolides, and chloramphenicol (a poor if at all a substrate of the pump MexXYOprM), the PA5471-70 operon is overexpressed (13) . This induction process has been proposed to rely on a sophisticated transcription attenuation mechanism that involves a short leader peptide, PA5471.1, whose coding sequence is located 5= upstream of the PA5471-70 transcript (14) . In the absence of drug exposure, PA5471.1 was predicted to form a stem-loop structure with adjacent sequences on the leader mRNA ahead of PA5471-70, which coexists with a terminator-like second stem-loop thought to attenuate PA5471-70 transcription by RNA polymerase (14) . Antibiotic interference with the translation process, possibly up to a point where ribosomes stall, would prevent the formation of these secondary mRNA structures and thus allow PA5471 gene expression and subsequent mexXY activation (14) . The PA5471 product, recently renamed ArmZ (for antirepressor MexZ), was found to physically interact with and to negatively modulate the activity of MexZ, the local repressor of the operon mexXY (15, 16) . The MexZ protein, which binds as a dimer to the divergent overlapping promoters of mexZ and mexXY in the mexZ-mexXY intergenic region, would be relieved from its DNA binding site through its interaction with ArmZ, thus resulting in hyperexpression of mexXY (15) . Although this two-step regulatory pathway is activated when P. aeruginosa is challenged with protein synthesis inhibitors, some of which are poor MexXY-OprM substrates, no evidence has been obtained to indicate that these inducing agents directly interact with MexZ independently of ArmZ (i.e., with basal, uninduced PA5471 gene expression) (17) . The constitutive overproduction of the proteins MexXY is generally associated with a 2-to 16-fold increase in the MICs of pump substrates (18, 19) . In addition to CF and non-CF clinical MexXY-OprM-overproducing strains found to harbor mutations inactivating the gene mexZ (e.g., indels, premature stop codons) or its product, MexZ (e.g., amino acid substitutions), isolates harboring intact (wild-type) mexZ genes have repeatedly been reported (19) (20) (21) (22) (23) (24) (25) but have rarely been characterized (26) . The observation that MexXY-OprM-upregulated mutants with defective protein synthesis can be selected in vitro on aminoglycoside (7, 26, 27) or a peptide deformylase inhibitor (28) suggested that such mutants, called agrW1, to differentiate them from mexZ mutants (dubbed agrZ), might be hypovirulent and thus poorly relevant in the clinic setting because of impaired fitness. Recently, our group reported that single amino acid changes in the response regulator ParR or the sensor kinase ParS of the two-component regulatory system ParRS may result in overexpression of both the mexXY operon and the lipopolysaccharide modification locus arnBCADTEF-ugd, along with decreased transcription of the gene for the porin OprD (24) . Mutants (called agrW2) harboring alterations in ParRS have been identified in the clinical setting (24, 29) , some of which were from severely ill patients admitted to intensive care units (ICU). The objective of the present study was to evaluate the prevalence of and to better characterize the three known types of MexXYOprM-overexpressing strains (i.e., agrZ, agrW1, and agrW2) in a collection of genotypically characterized clinical strains of P. aeruginosa resistant to aminoglycosides.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The strains and plasmids used in this study are listed in Table 1 . In addition, 92 nonconsecutive clinical P. aeruginosa isolates were selected from our laboratory collection. These strains, which were collected between 2001 and 2009 at the University Hospital of Besançon (France), were chosen for their typical MexXY-OprM-dependent resistance profile, characterized by an at least 2-fold increase in the MIC of three or more of the following substrates compared with wild-type strain PAO1: tobramycin (Ն1 g ml Ϫ1 ), amikacin (Ն8 g ml Ϫ1 ), apramycin (Ն32 g ml Ϫ1 ), ciprofloxacin (Ն0.5 g ml Ϫ1 ), and/or cefepime (Ն8 g ml Ϫ1 ). Multidrug-resistant bacteria exhibiting elevated resistance to amikacin (Ն128 g ml Ϫ1 ), apramycin (Ն512 g ml Ϫ1 ) and/or cefepime (Ն64 g ml Ϫ1 ) were not retained because of probable expression of enzymatic mechanisms. All the bacterial cultures were grown in Mueller-Hinton broth (MHB) with adjusted concentrations of Ca 2ϩ (from 20 to 25 mg/liter) and Mg 2ϩ (from 10 to 12.5 mg/liter) (Becton, Dickinson and Company, Cockeysville, MD), or on Mueller-Hinton agar (MHA; Bio-Rad, Marnes la Coquette, France). Recombinant plasmids were introduced into P. aeruginosa strains by triparental matings and mobilization via the broad-host-range vector pRK2013 harbored by Escherichia coli HB101 (30) . Transconjugants were selected on pseudomonas isolation agar (PIA; Becton, Dickinson and Company) supplemented with 150 g ml Ϫ1 ticarcillin, 200 g ml Ϫ1 tetracycline, or 2,000 g ml Ϫ1 streptomycin, as required. Transformants of E. coli were selected on MHA containing 100 g ml Ϫ1 ampicillin, 15 g ml Ϫ1 tetracycline, or 50 g ml Ϫ1 streptomycin. Growth curves of selected P. aeruginosa strains were established in triplicates by monitoring the absorbance at 600 nm of bacteria developing aerobically in 30 ml MHB at 37°C or 44°C under vigorous shaking (250 rpm). Guénard et al.
Antibiotic susceptibility testing. The MICs of selected antibiotics were determined by the standard serial 2-fold dilution method in MHA with an inoculum of 10 4 CFU per spot, as recommended (31) . Colistin MICs were determined by the macrodilution MHB procedure (31) . Growth was assessed visually after 18 h of incubation at 35°C to 37°C.
Mapping of mexZ mutations. The three-dimensional (3D) structure of MexZ (32) is available in the protein data bank (PDB; 2WU1; http: //www.rcsb.org/pdb/home/home.do). Its structure has been solved in the H32 space group with one monomer per unit cell. We generated the functional dimer by application of a crystallographic symmetry to analyze the consequences of the different mutations at the interface. In addition, to be able to analyze the DNA binding surface, a model was built of MexZ in complex with DNA. For that purpose, a search for DNA-bound TetR family regulators was performed with the PDB database, resulting in 4 different structures. The one presenting the smallest RMSD (root mean square deviation) with the MexZ monomer was further used as a template. It was the TetR/ DNA structure complex (PDB code 1QPI) (33) . The MexZ/DNA model was built by direct superposition of the two MexZ monomers on the two TetR ones by using the coot program (34) . With 29% of sequence homology between the two proteins, the superposition led to an RMSD of 12 Å, calculated on the 2 times 135 common C␣ atoms. Mutations found in clinical strains were visualized on both the free and DNA-bound models of MexZ by using MacPyMol software (DeLano Scientific, LLC).
Alignment of the protein MexZ with various TetR-like homologs. Multiple sequence alignment of the MexZ protein from P. aeruginosa was performed with homologs from different species by using the ClustalW2 software (http://www.ebi.ac.uk/Tools/msa/clustalw2/) in order to identify conserved regions. The different sequences were retrieved from the UniProt database (http://www.uniprot.org/uniprot/), and Jalview software was used to edit the alignments (35) .
Chromosomic complementation with full-length parRS. The parRS loci of strains exhibiting mutations in the gene parS were amplified by PCR from genomic DNA using the primers CloparRSC1/CloparRSC2 or CloparRSBamHIS1/CloparRSHindIIIS2 ( Table 2 ). The resulting DNA fragments were cloned either in pCR2.1 and next ligated to the EcoRV/ SpeI restriction sites of plasmid mini-CTX1 or were cloned directly in BamHI/HindIII-restricted mini-CTX1 (36). The recombinant plasmids were then transferred from E. coli CC118 to P. aeruginosa strain CM096 (PAO1⌬parRS) by conjugation with subsequent selection on tetracycline-PIA plates, to allow their chromosomal insertion into the attB site.
Gene transcript quantification by RT-qPCR. Specific gene expression levels were measured by real-time, quantitative PCR (RT-qPCR) after reverse transcription, as described previously (37) . Briefly, 2 g of total RNA was reverse transcribed with ImpromII reverse transcriptase as specified by Promega (Madison, WI). The amounts of specific cDNA were assessed in a Rotor Gene RG6000 real-time PCR instrument (Qiagen, Courtaboeuf, France) by using the QuantiFast SYBR PCR green kit (Qiagen), primers designed from the sequence in the Pseudomonas Genome Database, version 2 (Table 2) , and rpsL transcripts as internal controls. The mRNA levels of target genes were normalized for each strain with those of rpsL and expressed as a ratio (the fold change) compared to that of wild-type strain PAO1, used as the reference. Mean gene expression values were calculated from two independent bacterial cultures, each assayed in duplicate. As established previously, transcript levels of mexY that were Ն4-fold above that of strain PAO1 were considered significantly increased in clinical strains (9) . Well-characterized MexXY-overproducing mutants derived from PAO1 (CMZ091, PAOW1, and PAOW2) were used as positive controls to assess the overexpression of genes mexY, PA1797, PA5471, and arnA (24) .
Genotype analysis. The clonal relatedness of isolates was investigated by using Clondiag chips (Alere, Sèvres, France), which allows the identification of 14 single nucleotide polymorphisms (SNPs) in the core genome of P. aeruginosa. A genetic fingerprint (referred to as the hexadecimal code) was assigned to each strain and corresponded to the SNP combination found (38) .
RESULTS AND DISCUSSION
Selection of clinical strains overproducing MexXY. In order to characterize the different types of mexXY-upregulated mutants occurring in the clinical setting, we screened a collection of 92 P. aeruginosa isolates that exhibited a reduced susceptibility to typical MexXY-OprM substrates, including aminoglycosides (tobramycin, amikacin, apramycin), ciprofloxacin, and/or cefepime. Subsequent RT-qPCR experiments confirmed that all the selected bacteria overexpressed the gene mexY significantly above the wildtype reference strain PAO1 expression level. As demonstrated by SNP analysis with Clondiag chips (Alere), 42 strains were unique, while 9, 1, 2, 1, 1, and 1 other were represented by 2, 3, 4, 5, 6, and 10 isolates, respectively. Incidentally, these genotyping experiments pointed to the spread and persistence for years of several MexXY-OpM-overproducing clones in the hospital (data not shown). Finally, 57 genotypically distinct strains were retained for further investigations. As reflected by the MIC 50 values shown in Table 3 , the median resistance levels to MexXY-OprM substrates were close to those of typical in vitro-selected agrZ (CMZ091), agrW1 (PAOW1), and agrW2 (PAOW2) mutants. Most of these bacteria were susceptible to tobramycin (91%) and amikacin (84%) according to the current CLSI breakpoints, and they were more resistant to cefepime than to ceftazidime, as reported previously (9) . For apramycin, which is recalcitrant to many aminoglycoside-modifying enzymes, the MIC values were Ն32 g ml Ϫ1 in 55 strains of the selection (96.5% positivity).
mexZ-deficient mutants. Sequence analysis of mexZ, which encodes the local repressor of the operon mexXY, revealed that Table S1 in the supplemental material).
To better understand how the 13 mutations found in MexZ impact its activity, we mapped these variations in our models of freeand DNA-bound MexZ structures (Fig. 1) . The mutated residues could be classified into three different groups with respect to their location in the folded protein. Because they affect the dimer interface, the first group of mutations (Gly172Asp, Gly195Glu, and Ser198Ile) are predicted to strongly impair the dimerization of MexZ and its subsequent binding to the regulatory sequences upstream of mexXY. Of note, Gly195Glu was also identified in an extremely drug-resistant (XDR) international epidemic clone belonging to the same sequence type, ST175 (39), as strain 2508 and 4 clonally related isolates originally selected for this study (data not shown). In a future study, sequencing of mexZ genes from ST175 strains collected in various countries could confirm whether Gly195Glu is a signature for this successful clonal complex.
Mutations of the second group, which mapped in the N-terminal helix-turn-helix domain of MexZ (Thr32Asn, Gly46Ser, and Gly50Asp) are also expected to abrogate DNA binding. It should be noted that Thr32Asn was associated with group 1 mutation Ser198Ile in strain 4465. Finally, mutations of the third group were distributed all along the rest of the structure. All of them except Leu128Met are assumed to disturb the 3D structure of MexZ, because of their location in the core of the structure (Cys59Tyr, Phe192Tyr) or at helix interfaces (Ile16Thr, Ala38Val, Val48Ala, Ala144Val). Phe192Tyr was associated with group 1 mutation Gly172Asp in strain 3245. Val48Ala was previously reported in MexXY-overexpressing multidrug-resistant P. aeruginosa isolates from Germany (40) . In addition to pure structural effects, some additional points should be noted. Phe192 takes part in the antibiotic binding pocket present in most members of the TetR family, even if it has been suggested that MexZ does not interact with antibiotics even though the cavity is present (32) . Cys59 is at the bottom of the external helix (␣4) that is supposed to transmit the protein conformational changes to its DNA binding domain (41) . Its mutation into Tyr could rigidify the helix locally and abrogate this transmission. Ala38 is very close to the DNA fragment in the complex model. Consequently, it could also be considered a DNA binding actor, as structure modifications not taken into account in our model can occur when MexZ binds to DNA. Finally, the consequence of the last mutation, Leu128Met in strain 3135, is more difficult to explain, as it is located at the outer surface of the molecule. Nevertheless, in the structure of SimR (42), a TetR family transcriptional regulator from Streptomyces antibioticus, a two-helix insertion before the C-terminal helix and an N-terminal extension that covers the region containing the equivalent residue to Leu128 is supposed to play a regulatory role. Thus, it can be hypothesized that the Leu128Met change disturbs the regulatory function of MexZ, maybe via its interaction with another partner. agrW1-type mutants. As reported above, 13 MexXY-OprM overproducers exhibited a wild-type, intact repressor MexZ compared with PAO1 and PA14. RT-qPCR experiments were performed to characterize these strains further (Table 4 ). Strongly a According to the current CLSI breakpoints for tobramycin (S, Յ4 g/ml; R, Ն16 g/ml), amikacin (S, Յ16 g/ml; R, Ն64 g/ml), ciprofloxacin (S, Յ1 g/ml; R, Ն4 g/ml), cefepime (S, Յ8 g/ml; R, Ն32 g/ml), ceftazidime (S, Յ8 g/ml; R, Ն32 g/ml), ticarcillin (S, Յ16 g/ml; R, Ն128 g/ml). I, intermediate; ND, not defined.
FIG 1 Three-dimensional illustration of MexZ mutations, localized on the
MexZ/DNA model built for this study. The two molecules of the dimer are colored green and brown, respectively. Residues are represented by spheres in yellow for those located at the dimer interface, in blue for those located at the protein-DNA interface, and in red for all the other.
supporting the notion that 8 strains could be classified as agrW1-type mutants, expression levels of the gene PA5471, which codes for the antirepressor ArmZ (16), turned out to be 3.5-to 15.6-fold higher in these bacteria than in PAO1 (levels were increased 6.1-fold in the in vitro-selected mutant PAOW1 [ Table 4 ]). We thus looked for mutations in the loci already known to affect ribosomal functioning and to trigger constitutive, drug-independent activation of the operon mexXY through the PA5471 gene product. However, analysis of the coding sequences of genes rplA (7), rplY (27) , fmt (28) , and folD (28), as well as of the promoter region of the rplU-rpmA operon (26), failed to reveal significant alterations (i.e., nonsynonymous mutations, nucleotide insertions or deletions, or premature stop codons) compared with strains PAO1 and PA14. This result was not surprising per se, as multiple drugdependent and drug-independent events are known to activate PA5471 expression as far as the translational machinery is perturbed (43) . Since the mexXY operon is activated via a transcription attenuation mechanism involving the nucleotide sequence of the leader peptide PA5471.1 when ribosomes are stalling (14), we made the assumption that some ribosome-perturbing mutations might affect protein synthesis and growth rates. Indeed, alteration of rplA, rplY, fmt, folD, or the rplU-rpmA promoter region negatively impacts the fitness of P. aeruginosa (7, 26, 27, 44) . Consistent with our hypothesis, 5 of the 8 clinical strains (2405, 2946, 3136, 3564, and 5013) exhibited a longer lag phase, slower growth rates, and/or earlier onset of stationary phase than PAO1 at 37°C (Fig.  2A) . The deficient fitness of these strains was much more evident when the incubation was performed at 44°C (Fig. 2B) , a condition which almost inhibited their growth. The characterization of ribosomal mutations responsible for MexXY derepression in strains 3136, 3564, and PAOW1 is currently in progress (unpublished data). Contrasting with these findings, the 3 remaining strains, 3452, 4192, and 4592, multiplied like PAO1 at both temperatures ( Fig. 2A and B) , suggesting that all the PA5471-inducing mutations are not necessarily associated with a significant fitness cost for P. aeruginosa. A deletion in PA5471.1 leads to upregulation of PA5471. Sequencing of the 367-bp intergenic region between PA5472 and PA5471 did not reveal mutations in the agrW1 strains except in 4192, where the 42-bp coding sequence of the leader peptide gene PA5471.1 was found to be disrupted by a 7-bp deletion (⌬16 -22). In agreement with this, Morita et al. demonstrated by in vitro site-directed mutagenesis that interference with gene PA5471.1 translation results in PA5471 gene overexpression in strain PAO1 (14) . In the absence of mutations (e.g., generating premature stop codons), the wild-type PA5471.1 transcript was predicted to be involved in a stem-loop structure (named PA5471.1-2) on the nascent mRNA ahead of gene PA5471, which coexists with a second stem-loop (PA5471.1 3-4), with characteristics of putative transcription terminators. This presumed structure would prevent the transcription of the PA5471-70 operon (14) . Because the 7-bp deletion found in strain 4192 would preclude the formation of the proposed PA5471.1-2 structure, other mRNA base-pairing rearrangements might lead to the disruption of the uracyl-rich transcription terminator and promote high-level constitutive expression of genes PA5471-70 (14) . If confirmed, the mechanism found in strain 4192 would artificially reproduce some of the conformational changes occurring in the leader region of PA5471 mRNA when the transcriptional and the translational rates are perturbed (uncoupled) by antibiotics.
agrW2-type mutants. The 5 remaining strains (2756, 2794, 3562, 3726, and 3728) showed increased transcript levels of genes PA1797 and arnA due to alteration of the sensor kinase ParS from the two-component system ParRS (24) . Confirming recent data on imipenem-resistant ICU strains (29) , most of the mutations mapped in the periplasmic domain (R83K, L99P) or in the second transmembrane segment (L137P, V152A, A138T) of ParS, which is known to be important for signal transduction. The A168V Table S1 in the supplemental material). d Amino acid change activating sensor ParS (see Table S1 ). e Probable additional enzymatic mechanism of resistance.
change harbored by strain 2756 was located in the HAMP (histidine kinase, adenylyl cyclase, methyl-accepting chemotaxis proteins and phosphatases) domain, which physically connects the signal-sensing/transducing input functions of periplasmic and transmembrane regions to the kinase output functions of the cytoplasmic domain (45) . It should be noted that mutations at positions L137 (24) and A138 (29) have already been associated with ParRS-dependent mexXY overexpression in clinical strains. Of note, A138T coexisted with R83K in strain 3728, indicating that several mutations may accumulate in the parS gene. To confirm the role played by the aforementioned mutations in mexXY operon upregulation, the mutated parRS loci were cloned and inserted as single copies in the attB site of PAO1⌬parRS (mutant CM096) chromosome. As expected, the mutated parRS increased the resistance of CM096 to some or all of the MexXY-OprM substrates tested, as well as to imipenem, a result consistent with the observation that, when activated, the two-component system ParRS negatively regulates porin OprD gene expression and thus promotes carbapenem resistance (24, 29) (see Table S2 in the supplemental material). In contrast, the ParS sequence polymorphism found in strains 2946 (R155H) and 3136 (A82T) did not influence the CM096 resistance levels significantly, suggesting no or faint activation of ParS in these strains, although the mutations lie in the HAMP and the periplasmic sensor domains, respectively, and despite a modest overexpression of genes PA1797 and arn in strain 2946 (Table 4; see also Table S2 ). Finally, as noted previously (24) , mutational activation of ParRS was accompanied in some clinical agrW2 strains by a marginal increase in the colistin MIC (from 2-to 4-fold above that for PAO1 [ Table 4 ]).
Conclusions. The present study shows that a variety of specific and aspecific mutations affecting three distinct regulatory pathways actually lead to the overexpression of efflux system MexXY and to increased aminoglycoside resistance in clinical strains of P. aeruginosa. These pathways involve the local repressor MexZ (agrZ-type mutants), the MexZ antirepressor ArmZ (agrW1-type mutants), and the two-component regulatory system ParRS (agrW2-type mutants). Consistent with previous data (8, 19, 20, 22, 23, 39, (46) (47) (48) (49) (50) (51) , we found that most of the clinical MexXYoverproducing strains harbored mutations that inactivated the gene mexZ or compromised the activity of its product through amino acid substitutions concentrating in positions that are conserved in TetR regulators, including the DNA binding and the dimerization domains (see Fig. S1 in the supplemental material). It should be noted that mutational activation of the PA5471-dependent or/and the ParRS-dependent regulatory pathways was not systematically investigated in the mexZ-deficient strains, which may have led to an underestimation of potential double or triple agrZ agrW1 agrW2 mutants in the clinical setting. In vitro Because of the formation of bacterial aggregates, growth of strain 4192 could not be reliably monitored by spectrophotometry.
inactivation of the mexZ gene in laboratory mutants PAOW1 (data not shown) and PAOW2 (24) of the agrW1 and agrW2 types, respectively, could not demonstrate additive effects of the different MexXY-activating mutations on aminoglycoside resistance levels. Therefore, though the occurrence of such double or triple mutants cannot be ruled out in patients, their therapeutic relevance is expected to be the same as those of single mutants. We and others (21, 22) failed to identify mutations in the mexZmexXY intergenic regions of MexXY overproducers, which is somewhat intriguing. Since the expression of mexZ and mexXY is governed by overlapping promoter sequences encompassing the 20-bp palindromic binding site of repressor MexZ (15), a plausible explanation would be that mutations downregulating mexZ also negatively influence mexXY expression. Consistent with this, we found that a 3-bp deletion in the region where repressor MexR binds to the merR and mexA overlapping promoters downregulates the expression of operon mexAB-oprM and decreases antibiotic resistance in clinical P. aeruginosa (52) . More surprising was the observation that agrW1 mutants may survive in the clinical setting while being deficient in protein synthesis. With one exception (26) , such mutants have not been reported previously to infect or colonize patients. Unfortunately, the clinical data associated with our collection were not sufficient to determine if some agrW1 mutants remained pathogenic (i.e., were responsible for infections and not just colonization). One can imagine that those with unaffected growth rates may retain the ability to multiply actively in the immunocompromised host. Although there is increasing evidence that multiple ribosome-targeting mutations may result in PA5471-dependent upregulation of mexXY (7, (26) (27) (28) , it is clear from this study that mutational disruption of the leader peptide PA5471.1, encoded by the untranslated region (5= UTR) upstream of the gene PA5471, can also be exploited by P. aeruginosa to develop multidrug resistance. Other examples of mutation-driven shortcuts in ribosome-mediated attenuation of resistance genes have been reported for other organims [e.g., (ermC)] (53). Whether the 7-bp deletion characterized in strain 4192 prevents the formation of a terminator-like stem-loop ahead of operon mexXY or forces the ribosome to pause, allowing mexXY transcription, is unclear at the moment. Finally, this work confirmed the clinical relevance of agrW2 mutants, which combine an efflux-based resistance to aminoglycosides, cefepime, and ciprofloxacin with a decreased outer membrane permeability to carbapenems (24) . In agreement with these findings, similar mutants were recently isolated from patients in intensive care units (29) . Further investigations will determine if, in addition to the very prevalent agrZ mutants (48, 49) , agrW1 and agrW2 strains also occur in cystic fibrosis patients and enable P. aeruginosa to adapt to iterative aminoglycoside treatments in a context of chronic infection.
